Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy

As of December 31, 2023, the FDA had become aware of 22 cases of T-cell cancers that occurred after treatment with CAR-T products. For now, such cancers appear to be relatively rare adverse events.